Table 1.
Patient demographics and baseline tumor characteristics
| Characteristics | Tepotinib 215 mg once daily (n = 3) | Tepotinib 300 mg once daily (n = 3) | Tepotinib 500 mg once daily (n = 6) | Total (n = 12) |
|---|---|---|---|---|
| Median age, years (range) | 60 (53–72) | 62 (57–67) | 69.5 (53–75) | 64.5 (53–75) |
| Male/female, n | 2/1 | 2/1 | 4/2 | 8/4 |
| ECOG PS 0/1, n | 3/0 | 2/1 | 4/2 | 9/3 |
| Primary tumor site, na | ||||
| Appendix | 0 | 1 | 0 | 1 |
| Anal cancer | 0 | 0 | 1 | 1 |
| Biliary tract | 0 | 1 | 0 | 1 |
| Breast | 1 | 0 | 0 | 1 |
| Esophagus | 1 | 0 | 0 | 1 |
| Lung | 0 | 1 | 0 | 1 |
| Rectum | 0 | 0 | 1 | 1 |
| Stomach | 0 | 0 | 2 | 2 |
| Thoracic esophagus | 0 | 0 | 1 | 1 |
| Urachus | 0 | 0 | 1 | 1 |
| Unknown | 1 | 0 | 0 | 1 |
| Prior lines of anticancer drug therapy, n | ||||
| 0 | 0 | 0 | 1 | 1 |
| 1–2 | 0 | 0 | 2 | 2 |
| ≥3 | 3 | 3 | 3 | 9 |
aAll tumors were adenocarcinoma and stage IV, apart from two squamous cell carcinomas and one tumor of unknown stage.
ECOG PS, Eastern Cooperative Oncology Group performance status.